Leukeran (chlorambucil) / GSK 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...6789101112131415161718»
  • ||||||||||  Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen
    New trial:  GAIRI: Gazyva Infusion Reaction Investigation (clinicaltrials.gov) -  May 21, 2018   
    P=N/A,  N=104, Recruiting, 
  • ||||||||||  Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
    Enrollment closed, Trial primary completion date:  Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (clinicaltrials.gov) -  Oct 12, 2017   
    P=N/A,  N=100, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=450 --> 600 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Dec 2017
  • ||||||||||  Calquence (acalabrutinib) / AstraZeneca
    Enrollment closed, Combination therapy, Monotherapy:  ELEVATE-TN: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na (clinicaltrials.gov) -  Feb 16, 2017   
    P3,  N=535, Active, not recruiting, 
    Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Active, not recruiting
  • ||||||||||  Leukeran (chlorambucil) / GSK, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
    Enrollment closed, Trial primary completion date, Combination therapy:  Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma (clinicaltrials.gov) -  Jul 28, 2016   
    P2,  N=112, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Mar 2016
  • ||||||||||  Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
    Trial primary completion date:  Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (clinicaltrials.gov) -  Jul 19, 2016   
    P=N/A,  N=100, Recruiting, 
    Active, not recruiting --> Recruiting | Trial primary completion date: May 2016 --> Oct 2018 Trial primary completion date: Sep 2015 --> Sep 2016
  • ||||||||||  Calquence (acalabrutinib) / AstraZeneca
    Trial primary completion date, Combination therapy, Monotherapy:  ELEVATE-TN: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na (clinicaltrials.gov) -  Apr 27, 2016   
    P3,  N=510, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Aug 2019 --> Dec 2019